Angion Expands Executive Team to Support the Ongoing and Future Clinical Development of ANG-3777
November 04, 2019 10:00 ET
|
Angion Biomedica Corp
UNIONDALE, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury, today...
Angion Announces Several Strategic Additions to its Management Team to Support the Future Development and Commercialization of ANG-3777
October 14, 2019 10:39 ET
|
Angion Biomedica Corp
UNIONDALE, N.Y., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp., a clinical stage biopharmaceutical company developing a first-in-class therapy targeting acute kidney injury, today...
Angion to Present Late-Breaking Data on ANG-3777 in Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
October 11, 2019 10:05 ET
|
Angion Biomedica Corp
UNIONDALE, N.Y., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury, today...
Angion Awarded $4.76 Million Department of Defense Grant for Chronic Kidney Disease Drug Candidate ANG-3070
April 03, 2019 08:00 ET
|
Angion Biomedica Corp
UNIONDALE, N.Y., April 03, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp., a clinical stage biopharmaceutical company targeting acute and chronic organ injuries, announced it had received a $4.76...
Angion Biomedica Corp to Provide Corporate Overview at the 8th Annual SVB Leerink Healthcare Conference
February 26, 2019 09:14 ET
|
Angion Biomedica Corp
UNIONDALE, N.Y., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp., a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, today announced...
Angion Completes Equity Financing and Appoints Senior Executives
January 04, 2019 12:36 ET
|
Angion Biomedica Corp
Closes $35 million financing to advance Phase 2 and Phase 3 programs with drug candidate ANG-3777Announces appointments of Jay R. Venkatesan, M.D. as President and Chief Executive Officer, and John F....